Neos Therapeutics Inc. (NASDAQ:NEOS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The brokerage currently has a $7.75 target price on the stock. Zacks Investment Research’s target price would indicate a potential upside of 16.19% from the company’s previous close.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Separately, BMO Capital Markets restated a “buy” rating and issued a $15.00 target price on shares of Neos Therapeutics in a report on Tuesday, September 20th. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $20.94.
Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 6.67 on Thursday. The company’s market cap is $107.19 million. Neos Therapeutics has a 1-year low of $6.33 and a 1-year high of $18.84. The company’s 50-day moving average is $7.05 and its 200 day moving average is $8.63.
Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by $0.49. The firm earned $1.49 million during the quarter, compared to the consensus estimate of $1.48 million. Neos Therapeutics had a negative return on equity of 80.10% and a negative net margin of 968.81%. Equities analysts anticipate that Neos Therapeutics will post ($5.39) EPS for the current year.
In related news, CFO Richard I. Eisenstadt purchased 3,710 shares of Neos Therapeutics stock in a transaction that occurred on Thursday, August 25th. The shares were bought at an average price of $6.82 per share, with a total value of $25,302.20. Following the purchase, the chief financial officer now directly owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.85% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of NEOS. ProShare Advisors LLC increased its position in Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock worth $126,000 after buying an additional 1,233 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in Neos Therapeutics during the second quarter worth approximately $200,000. Teachers Advisors Inc. increased its position in Neos Therapeutics by 289.6% in the second quarter. Teachers Advisors Inc. now owns 21,924 shares of the company’s stock worth $203,000 after buying an additional 16,296 shares during the period. California State Teachers Retirement System increased its position in Neos Therapeutics by 140.1% in the second quarter. California State Teachers Retirement System now owns 28,815 shares of the company’s stock worth $267,000 after buying an additional 16,815 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock worth $353,000 after buying an additional 16,046 shares during the period. 37.73% of the stock is currently owned by institutional investors.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.